Qritive develops artificial intelligence solutions for digital pathology, providing fast interpretations of whole slide image scans to support cancer diagnosis. Its technology delivers results within seconds and covers multiple cancer types including colon, prostate, lymph node, and breast, along with tools for immunohistochemistry. The company’s solutions are CE certified and approved by Singapore’s Health Sciences Authority. Qritive was founded in 2017 by Dr. Aneesh Sathe and Dr. Kaveh Taghipour and maintains operations in San Diego (U.S.) and Pune (India). The firm raised $7.5M and intends to use proceeds to drive geographical expansion, broaden its product portfolio, and support regulatory clearances.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2023